Nikhil Lalwani Biography and Net Worth

President and Chief Executive Officer of ANI Pharmaceuticals

Mr. Lalwani is ANI’s President and Chief Executive Officer and a member of ANI’s Board. Prior to joining ANI in September 2020, Mr. Lalwani worked at Cipla Ltd (NSE: CIPLA), a global pharmaceutical company, from May 2012 to August 2020 where he held positions of increasing responsibility, including CEO of Cipla USA, CEO of InvaGen, Head of US Strategy, M&A & Integration, and Head of Cipla’s Global Respiratory business. In these roles, Mr. Lalwani developed and executed multi-year strategic growth plans for key products and facilitated successful acquisitions as Cipla entered the specialty pharmaceutical space. Prior to Cipla, Mr. Lalwani was an Associate Partner with McKinsey & Company serving pharmaceutical and healthcare companies across the world, and an engineer with Medtronic. Mr. Lalwani holds a B.S. in Electrical Engineering from Georgia Institute of Technology and an M.B.A. from the Wharton School at the University of Pennsylvania.

What is Nikhil Lalwani's net worth?: The estimated net worth of Nikhil Lalwani is at least $25.82 million as of September 15th, 2026. Mr. Lalwani owns 339,089 shares of ANI Pharmaceuticals stock worth more than $25,818,236 as of September 18th. This net worth approximation does not reflect any other investments that Mr. Lalwani may own. Learn More about Nikhil Lalwani's net worth.
How do I contact Nikhil Lalwani?: The corporate mailing address for Mr. Lalwani and other ANI Pharmaceuticals executives is 104 Carnegie Center Drive Suite 300, Princeton, NJ, 08540. ANI Pharmaceuticals can also be reached via phone at (218) 634-3500 and via email at [email protected]. Learn More on Nikhil Lalwani's contact information.
Has Nikhil Lalwani been buying or selling shares of ANI Pharmaceuticals?: During the past quarter, Nikhil Lalwani has sold $784,620.00 of ANI Pharmaceuticals stock. Most recently, Nikhil Lalwani sold 5,400 shares of the business's stock in a transaction on Tuesday, September 15th. The shares were sold at an average price of $71.00, for a transaction totalling $383,400.00. Following the completion of the sale, the chief executive officer now directly owns 339,089 shares of the company's stock, valued at $24,075,319. Learn More on Nikhil Lalwani's trading history.
Who are ANI Pharmaceuticals' active insiders?: ANI Pharmaceuticals' insider roster includes Stephen Carey (CFO), Stephen Carey (Senior Vice President, Finance and Chief Financial Officer), Meredith Cook (Senior Vice President, General Counsel and Corporate Secretary), Krista Davis (Senior Vice President and Chief Human Resources Officer), Chad Gassert (Senior Vice President, Corporate Development and Strategy), Ori Gutwerg (Senior Vice President, Generics), Thomas Haughey (Director), Nikhil Lalwani (Pres), Nikhil Lalwani (President and Chief Executive Officer), Matthew Leonard (Director), James Marken (Senior Vice President, Operations and Product Development), Christopher Mutz (Insider), Antonio Pera (Director), Thomas Rowland (SVP), Muthusamy Shanmugam (Head of R&D and COO of NJ Operations), Muthusamy Shanmugam (Head of R&D and COO), Renee Tannenbaum (Director), Jeanne Thoma (Director), and Patrick Walsh (Director). Learn More on ANI Pharmaceuticals' active insiders.
Are insiders buying or selling shares of ANI Pharmaceuticals?: During the last year, insiders at the specialty pharmaceutical company sold shares 40 times. They sold a total of 164,202 shares worth more than $13,033,430.60. The most recent insider tranaction occured on September, 15th when CEO Nikhil Lalwani sold 5,400 shares worth more than $383,400.00. Insiders at ANI Pharmaceuticals own 8.1% of the company. Learn More about insider trades at ANI Pharmaceuticals.
Information on this page was last updated on 9/15/2026.

Nikhil Lalwani Insider Trading History at ANI Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
9/15/2026	Sell	5,400	$71.00	$383,400.00	339,089
8/25/2026	Sell	5,400	$74.30	$401,220.00	344,489
5/11/2026	Sell	55,000	$77.57	$4,266,350.00	349,889
8/12/2025	Sell	56,960	$85.93	$4,894,572.80	411,219
11/26/2024	Sell	33,481	$57.99	$1,941,563.19	370,378
5/14/2024	Sell	16,669	$66.10	$1,101,820.90	377,505
3/8/2024	Sell	16,292	$67.13	$1,093,681.96	411,629
3/6/2024	Sell	28,965	$65.52	$1,897,786.80	444,981
8/15/2023	Sell	11,616	$61.13	$710,086.08	353,390
8/11/2023	Sell	56,666	$57.75	$3,272,461.50	353,390
3/21/2022	Buy	7,224	$27.69	$200,032.56

Nikhil Lalwani Buying and Selling Activity at ANI Pharmaceuticals

ANI Pharmaceuticals Company Overview

ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products. It markets its products through retail pharmacy chains, wholesalers, distributors and mail order pharmacies, group purchasing organizations, specialty pharmacies, and hospitals. ANI Pharmaceuticals, Inc. was incorporated in 2001 and is headquartered in Baudette, Minnesota.

Today's Range

Now: $76.14

$74.21

$77.41

50 Day Range

MA: $76.30

$70.19

$82.63

2 Week Range

Now: $76.14

$69.58

$98.04

Volume

1,160,356 shs

Average Volume

383,437 shs

Market Capitalization

$1.75 billion

P/E Ratio

16.41

Dividend Yield

N/A

Beta

0.45